title: Essential tremor-the most common movement disorder in older people.
abstract: Essential tremor (ET) affects approximately 4% of the population above 65 years of age. The traditional view that ET is a familial monosymptomatic disorder with a benign prognosis has recently been challenged, as it is now known to be a progressive and clinically heterogeneous condition with sporadic and familial forms. The pathogenesis of ET is not fully understood, though a disordered central mechanism is the most likely site of origin with possible modulation by muscle adrenoreceptors. The limited post-mortem studies have not shown consistent abnormalities in the brains of ET patients. ET is often misdiagnosed as Parkinson's disease, particularly in the older population. Tremor amplitude increases with age, accounting for substantial disability in older people. Current therapy (drugs and neurosurgery) has significant limitations in older people. A better understanding of its pathophysiology in the future will help in developing more effective therapy, including neuroprotective strategies.
authors.affiliation: Leicester General Hospital, Medicine for the Elderly, Leicester, UK. bthanvi@hotmail.com
authors.forename: Bhomraj
authors.initials: B
authors.lastname: Thanvi
authors.forename: Nelson
authors.initials: N
authors.lastname: Lo
authors.forename: Tom
authors.initials: T
authors.lastname: Robinson
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D003937:Diagnosis, Differential; D050483:Dopamine Plasma Membrane Transport Proteins; D020329:Essential Tremor / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D006801:Humans; D011324:Primidone / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D018726:Anti-Dyskinesia Agents; D000927:Anticonvulsants; D002257:Carbonic Anhydrase Inhibitors; D050483:Dopamine Plasma Membrane Transport Proteins; D001569:Benzodiazepines; D011324:Primidone; D001905:Botulinum Toxins